Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Veeram Securities Ltd
BSE:540252
|
IN |
|
S
|
Svenska Handelsbanken AB
STO:SHB B
|
SE |
|
H.U. Group Holdings Inc
TSE:4544
|
JP |
|
MBIA Inc
NYSE:MBI
|
US |
|
Oxley Holdings Ltd
SGX:5UX
|
SG |
|
Shanghai Eliansy Industry Group Corp Ltd
SSE:600836
|
CN |
|
P
|
PennantPark Floating Rate Capital Ltd
NYSE:PFLT
|
US |
|
T
|
Telkom SA SOC Ltd
JSE:TKG
|
ZA |
|
Ryanair Holdings PLC
ISEQ:RYA
|
IE |
|
L
|
Loma Negra Compania Industrial Argentina SA
BCBA:LOMA
|
AR |
|
Garden Reach Shipbuilders & Engineers Ltd
NSE:GRSE
|
IN |
Novan Inc
Change in Working Capital
Novan Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Change in Working Capital
$566k
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Change in Working Capital
-$12.7B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Change in Working Capital
-$455m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Change in Working Capital
-$5.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-81%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Change in Working Capital
-$7B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-39%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Change in Working Capital
-$8.1B
|
CAGR 3-Years
-2 063%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-22%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Change in Working Capital?
Change in Working Capital
566k
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Change in Working Capital amounts to 566k USD.
What is Novan Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-23%
Over the last year, the Change in Working Capital growth was -87%. The average annual Change in Working Capital growth rates for Novan Inc have been -56% over the past three years , -23% over the past five years .
